MMIT Reality Check on Non-Small Cell Lung Cancer Systemic Therapy (Aug 2021)

According to our recent payer coverage analysis for non-small cell lung cancer systemic therapy treatments treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for non-small cell lung cancer systemic therapy treatments shows that under the pharmacy benefit, about 39% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In February 2021, the FDA gave an additional indication to Libtayo for the first-line treatment of people with advanced NSCLC whose tumors have high PD-L1 expression of tumor proportion score ≥ 50%, as determined by an FDA-approved test.

by Matt Breese

0

0

0 Comments

0

0

• Reality Check